Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1
- PMID: 17875698
- DOI: 10.1158/0008-5472.CAN-06-2220
Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1
Abstract
Astrocytoma (glioma) formation in neurofibromatosis type 1 (NF1) occurs preferentially along the optic pathway during the first decade of life. The molecular basis for this unique pattern of gliomagenesis is unknown. Previous studies in mouse Nf1 optic glioma models suggest that this patterning results from cooperative effects of Nf1 loss in glial cells and the action of factors derived from the surrounding Nf1+/- brain. Because CXCL12 is a stroma-derived growth factor for malignant brain tumors, we tested the hypothesis that CXCL12 functions in concert with Nf1 loss to facilitate NF1-associated glioma growth. Whereas CXCL12 promoted cell death in wild-type astrocytes, it increased Nf1-/- astrocyte survival. This increase in Nf1-/- astrocyte survival in response to CXCL12 was due to sustained suppression of intracellular cyclic AMP (cAMP) levels. Moreover, the ability of CXCL12 to suppress cAMP and increase Nf1-/- astrocyte survival was a consequence of mitogen-activated protein/extracellular signal-regulated kinase kinase-dependent inhibition of CXCL12 receptor (CXCR4) desensitization. In support of an instructive role for CXCL12 in facilitating optic glioma growth, we also show that CXCL12 expression along the optic pathway is higher in infant children and young mice and is associated with low levels of cAMP. CXCL12 expression declines in multiple brain regions with increasing age, correlating with the age-dependent decline in glioma growth in children with NF1. Collectively, these studies provide a mechanism for the unique pattern of NF1-associated glioma growth.
Similar articles
-
CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.J Neuroimmunol. 2010 Jul 27;224(1-2):108-13. doi: 10.1016/j.jneuroim.2010.05.002. J Neuroimmunol. 2010. PMID: 20554030 Free PMC article.
-
Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.Neuro Oncol. 2015 Jun;17(6):843-53. doi: 10.1093/neuonc/nou329. Epub 2014 Dec 21. Neuro Oncol. 2015. PMID: 25534823 Free PMC article.
-
Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.Cancer Res. 2008 Dec 15;68(24):10358-66. doi: 10.1158/0008-5472.CAN-08-2506. Cancer Res. 2008. PMID: 19074905
-
Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.J Neurosci Res. 2019 Jan;97(1):45-56. doi: 10.1002/jnr.24250. Epub 2018 Apr 28. J Neurosci Res. 2019. PMID: 29704429 Free PMC article. Review.
-
Neurofibromin in the brain.J Child Neurol. 2002 Aug;17(8):592-601; discussion 602-4, 646-51. doi: 10.1177/088307380201700809. J Child Neurol. 2002. PMID: 12403558 Review.
Cited by
-
Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.Annu Rev Pathol. 2012;7:469-95. doi: 10.1146/annurev-pathol-011811-132441. Epub 2011 Nov 7. Annu Rev Pathol. 2012. PMID: 22077553 Free PMC article. Review.
-
Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.Hum Mol Genet. 2014 Dec 20;23(25):6712-21. doi: 10.1093/hmg/ddu389. Epub 2014 Jul 28. Hum Mol Genet. 2014. PMID: 25070947 Free PMC article.
-
Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma.J Biol Rhythms. 2017 Apr;32(2):121-129. doi: 10.1177/0748730417696788. Epub 2017 Mar 16. J Biol Rhythms. 2017. PMID: 28470120 Free PMC article.
-
Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development.Neurooncol Adv. 2025 Feb 16;7(1):vdaf040. doi: 10.1093/noajnl/vdaf040. eCollection 2025 Jan-Dec. Neurooncol Adv. 2025. PMID: 40134850 Free PMC article. Review.
-
A three-dimensional (3D) organotypic microfluidic model for glioma stem cells - Vascular interactions.Biomaterials. 2019 Apr;198:63-77. doi: 10.1016/j.biomaterials.2018.07.048. Epub 2018 Jul 30. Biomaterials. 2019. PMID: 30098794 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous